Aridis Pharmaceuticals, Inc.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC amended its Schedule 13G filing with the SEC covering its stake in Aridis Pharmaceuticals, Inc., under accession number 0001172661-26-005210. The filing is a passive-investor ownership update rather than a change in control, and the amended disclosure revises the fund's reported position in the pharmaceutical company. The update matters because 13G amendments signal shifts in institutional ownership that can affect liquidity and shareholder composition in a small-cap stock. Investors will watch for the specific share count and percentage disclosed in the amendment, and for any further 13G or 13D filings that would indicate a more active stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Aridis Pharmaceuticals, Inc.